Recombinant Human SLC2A1 protein

>90% as determined by SDS-PAGE

Please contact with the lab for this information.

A DNA sequence encoding the human SLC2A1 (Met251-Glu329) was fused with His tag

P11166

E.coli

Homo sapiens (Human)

10.15 kDa

Supplied as solution form in PBS pH 7.5 or lyophilized from PBS pH 7.5.

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Arterial tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder, mainly characterized by tortuosity and elongation of the large- and medium-sized arteries with predisposition to stenoses and aneurysms. ATS is caused by mutations in the SLC2A1 gene, encoding for the facilitative glucose transporter 1 (GLUT1) and is described typically in pediatric patients. The loss-of-function mutation in the gene encoding the facilitative glucose transporter GLUT1 (SLC2A1) causes arterial tortuosity syndrome via upregulation of the TGF-beta pathway in the arterial wall, a mechanism possibly causing vascular changes in diabetes. The SLC2A1 gene is an independent risk factor for PAD in type 2 diabetes.

Solute carrier family 2, facilitated glucose transporter member 1,Glucose transporter type 1, erythrocyte/brain,GLUT-1,HepG2 glucose transporter.

For research use only .